Clinical Trials
202 trialsPICC-3
Sun Yat-sen University
LIGHT
Sun Yat-sen University
Metronomic Oral Paclitaxel Monotherapy and Combined Immunotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose Exploration and Expansion Trial
Zhejiang Cancer Hospital
A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer
Shanghai Junshi Bioscience Co., Ltd.
NeoTOP
Sun Yat-sen University
SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma
Sun Yat-sen University
TRIPLE-PATH
Jinling Hospital, China
Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors
Shanghai Junshi Bioscience Co., Ltd.
Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma
Sun Yat-sen University
Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Sun Yat-sen University
(NeoScorch HN)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
FACT-TN
Sun Yat-sen University
WOLF
University of Pittsburgh
TORCH-iTNT
Fudan University
Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC
Hunan Province Tumor Hospital
Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients
Shanghai Pulmonary Hospital, Shanghai, China
Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer
Sun Yat-sen University
The Effect of Toripalimab Plus Radiotherapy in Patients With Operable Stage II-IIIA (N+) Non Small Cell Lung Cancer
Shanghai Chest Hospital
NEOTRIO-2
Second Affiliated Hospital, School of Medicine, Zhejiang University
PLUTO
Jinling Hospital, China
A Single-center Phase II Study to Investigate the Immune Maintenance Therapy Pattern in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Who Have Achieved MPR After Neoadjuvant Immunotherapy Combined With Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer
Sun Yat-sen University
InTRist
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase II Exploratory Study of Toripalimab Combined With SBRT in HER2-Negative Breast Cancer Patients With Insensitivity to Neoadjuvant Chemotherapy
Tianjin Medical University Cancer Institute and Hospital
Gemcitabine + Docetaxel + Toripalimab Induction in Epstein-Barr Virus (EBV) Associated Nasopharyngeal Carcinoma(NPC)
Stanford University
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer
University of Chicago
Study of Toripalimab for Limited-Stage Small Cell Lung Cancer Following Concurrent Chemoradiotherapy
Sun Yat-sen University
Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
First Affiliated Hospital of Zhejiang University
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
China Medical University, China
A Phase II Study of Utidelone With Toripalimab in Advanced Cervical Cancer
Zhongnan Hospital
Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung Cancer
Tianjin Medical University Cancer Institute and Hospital
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
Tang-Du Hospital
A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma
First Affiliated Hospital of Guangxi Medical University
Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02)
First Affiliated Hospital of Zhejiang University
Toripalimab for High-risk Locally Advanced Cervical Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
TUORA
Tianjin Medical University Second Hospital
A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer
Tongji Hospital
Toripalimab Combined With SBRT for NSCLC
Shanghai Pulmonary Hospital, Shanghai, China
Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Therapy in Patients With Resectable Non-small-cell Lung Cancer in China (LUNG-Nanjing01): a Single-arm, Single-centre, Phase 2 Trial
Jiangsu Cancer Institute & Hospital
A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital
The Optimal Radioimmunotherapy Combinations for Advanced TNBC
Sun Yat-sen University
BCIRT-01
Sun Yat-sen University
Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC
Tianjin Medical University Cancer Institute and Hospital
PICC
Sun Yat-sen University
Vedisertib (RC48/ADC) Combined With Toripalimab in Bladder-preserving Treatment
Qilu Hospital of Shandong University
Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
Emory University
OHAI-NMIBC-01
First Affiliated Hospital of Wenzhou Medical University
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With Toripalimab and Axitinib in Advanced RCC
Tianjin Medical University Second Hospital
A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University